AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

AC Immune S.A.NASDAQ: ACIU

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue remains negative

Q1 FY2026 cost of revenue was CHF 0, compared with CHF 0 a year earlier. Trailing-twelve-month cost of revenue was CHF 0.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025, down 229.1 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly cost of revenue holds near CHF 0 or moves back toward the trailing-twelve-month quarterly average of CHF 0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CHF 0— QoQ
Last fiscal yearDec 2025
CHF 0-100.0% YoY
LTMMar 2026
CHF 0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CHF · from the income statement

Latest · FY2025
0 CHF
Year-over-year change
-100.0%

Cost of Revenue vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 0.0% of revenue for ACIU, versus a peer median of 47.5%.
ACIU Competitors
Cost of Revenue for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$102.11M USD-27.2%-9.9%47.5%
CLLSCellectis S.A.LTM Mar 2026$12.33M USD+39.3%+4.9%18.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026$2.33M USD——7522.6%
ANNXAnnexon, Inc.LTM Mar 2026$1.9M USD———
MREOMereo BioPharma Group plcLTM Mar 2026$1.03M USD-5.2%—205.7%
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
ANROAlto Neuroscience, Inc.LTM Mar 2026$284K USD+67.1%+24.6%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$79K USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$66.6K USD———
ACIUAC Immune S.A.LTM Mar 2026CHF 0 CHF——0.0%
DRTSAlpha Tau Medical Ltd.LTM Mar 2026$0 USD—+8.0%—
Peer median (excluding ACIU) —+17.1%+4.9%47.5%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.